关键信息
-
基因名
clfB
- 应用
-
别名
Fibrinogen receptor B Fibrinogen-binding protein B
-
种属
Staphylococcus aureus
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q6GDH2
-
表达区间
45-542aa
-
分子量
69.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
ClfB, or Clumping Factor B, is a surface protein of Staphylococcus aureus, a significant human pathogen responsible for various infections ranging from skin conditions to severe systemic diseases. This protein plays a crucial role in the bacteria's ability to adhere to host tissues and evade immune responses by interacting with host proteins such as fibrinogen. Research on ClfB has gained momentum due to its potential as a target for vaccine development and therapeutic interventions. Understanding the structure, function, and immune response elicited by ClfB is essential for devising strategies to combat Staphylococcus aureus infections. Furthermore, given the rise of antibiotic resistance among Staphylococcus aureus strains, identifying novel approaches to disrupt its pathogenic mechanisms is critical. The study of ClfB-recombinant proteins seeks to elucidate its role in an infection, providing insights that could lead to new preventive measures and treatment options. By utilizing recombinant DNA technology to produce ClfB, researchers aim to explore its immunogenic properties and assess its potential as a vaccine candidate, thereby contributing to the broader fight against antibiotic-resistant bacterial infections.
